Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.
Beyond Air (NASDAQ: XAIR) has secured a national group purchasing agreement with Premier, Inc., effective July 15th, 2025. The agreement enables Premier's network of healthcare providers to access special pricing for Beyond Air's LungFit PH system and disposable NO2 Smart Filters.
The LungFit PH platform utilizes patented Ionizer™ technology to generate unlimited, on-demand nitric oxide from ambient air for ventilator delivery. The system operates on minimal power, equivalent to a 60-watt lightbulb, and includes Smart Filters that provide 12 hours of uninterrupted therapy. Premier serves two-thirds of U.S. healthcare providers, making this agreement significant for Beyond Air's market reach.
Beyond Air (NASDAQ: XAIR) ha ottenuto un accordo nazionale di acquisto di gruppo con Premier, Inc., valido dal 15 luglio 2025. Questo accordo consente alla rete di fornitori sanitari di Premier di accedere a prezzi speciali per il sistema LungFit PH di Beyond Air e per i filtri usa e getta NO2 Smart Filters.
La piattaforma LungFit PH utilizza la tecnologia brevettata Ionizer™ per generare quantità illimitate di ossido nitrico su richiesta a partire dall'aria ambiente, da somministrare tramite ventilatore. Il sistema funziona con un consumo energetico minimo, equivalente a una lampadina da 60 watt, e include filtri intelligenti che garantiscono 12 ore di terapia continua. Premier serve due terzi dei fornitori sanitari negli Stati Uniti, rendendo questo accordo particolarmente rilevante per la diffusione di Beyond Air sul mercato.
Beyond Air (NASDAQ: XAIR) ha asegurado un acuerdo nacional de compras grupales con Premier, Inc., vigente a partir del 15 de julio de 2025. Este acuerdo permite a la red de proveedores de atención médica de Premier acceder a precios especiales para el sistema LungFit PH de Beyond Air y los filtros desechables NO2 Smart Filters.
La plataforma LungFit PH utiliza la tecnología patentada Ionizer™ para generar óxido nítrico ilimitado y bajo demanda a partir del aire ambiental para su administración mediante ventilador. El sistema funciona con un consumo mínimo de energía, equivalente a una bombilla de 60 vatios, e incluye filtros inteligentes que proporcionan 12 horas de terapia continua. Premier atiende a dos tercios de los proveedores de salud en EE. UU., lo que hace que este acuerdo sea significativo para la expansión de Beyond Air en el mercado.
Beyond Air (NASDAQ: XAIR)는 2025년 7월 15일부터 발효되는 Premier, Inc.와의 전국 그룹 구매 계약을 체결했습니다. 이 계약을 통해 Premier의 의료 제공자 네트워크는 Beyond Air의 LungFit PH 시스템과 일회용 NO2 스마트 필터를 특별 가격으로 이용할 수 있습니다.
LungFit PH 플랫폼은 특허받은 Ionizer™ 기술을 활용하여 주변 공기에서 무제한으로 즉시 산화질소를 생성하여 인공호흡기에 공급합니다. 이 시스템은 60와트 전구와 맞먹는 최소한의 전력으로 작동하며, 12시간 연속 치료가 가능한 스마트 필터를 포함합니다. Premier는 미국 의료 제공자의 3분의 2를 서비스하고 있어 이번 계약은 Beyond Air의 시장 확장에 중요한 의미를 갖습니다.
Beyond Air (NASDAQ : XAIR) a conclu un accord national d'achat groupé avec Premier, Inc., effectif à partir du 15 juillet 2025. Cet accord permet au réseau de prestataires de soins de santé de Premier d'accéder à des tarifs préférentiels pour le système LungFit PH de Beyond Air ainsi que pour les filtres jetables NO2 Smart Filters.
La plateforme LungFit PH utilise la technologie brevetée Ionizer™ pour générer une quantité illimitée d'oxyde nitrique à la demande à partir de l'air ambiant, destiné à la ventilation. Le système fonctionne avec une consommation électrique minimale, équivalente à une ampoule de 60 watts, et comprend des filtres intelligents offrant 12 heures de thérapie continue. Premier dessert les deux tiers des prestataires de soins de santé aux États-Unis, ce qui rend cet accord particulièrement important pour la portée commerciale de Beyond Air.
Beyond Air (NASDAQ: XAIR) hat eine nationale Gruppen-Einkaufsvereinbarung mit Premier, Inc. abgeschlossen, die ab dem 15. Juli 2025 gilt. Diese Vereinbarung ermöglicht es dem Netzwerk von Gesundheitsdienstleistern von Premier, Sonderpreise für das LungFit PH-System von Beyond Air und die Einweg-NO2 Smart Filters zu erhalten.
Die LungFit PH-Plattform nutzt die patentierte Ionizer™-Technologie, um unbegrenzt und bedarfsgerecht Stickstoffmonoxid aus der Umgebungsluft für die Beatmungsgerätebereitstellung zu erzeugen. Das System arbeitet mit minimalem Stromverbrauch, vergleichbar mit einer 60-Watt-Glühbirne, und beinhaltet Smart Filters, die 12 Stunden ununterbrochene Therapie bieten. Premier betreut zwei Drittel der US-Gesundheitsdienstleister, was diese Vereinbarung für Beyond Airs Marktreichweite bedeutend macht.
- Access to Premier's extensive network covering two-thirds of U.S. healthcare providers
- Special pricing agreement streamlines sales process for LungFit PH system
- Technology offers unlimited, on-demand nitric oxide generation compared to cylinder-based systems
- None.
Insights
Beyond Air's Premier GPO agreement significantly expands LungFit PH's market access, streamlining sales to major hospital networks.
Beyond Air has secured a national group purchasing agreement with Premier, Inc., giving Premier's vast network of U.S. healthcare providers access to preferential pricing for the LungFit PH system. This agreement represents a significant commercial advancement for Beyond Air, as Premier serves approximately two-thirds of all healthcare providers in the United States.
The LungFit PH system offers a revolutionary approach to nitric oxide delivery compared to traditional cylinder-based systems. Using patented Ionizer™ technology, it generates nitric oxide on-demand from ambient air, requiring only the power equivalent to a 60-watt lightbulb. The system delivers NO concentrations between 0.5-80 ppm for treating persistent pulmonary hypertension of the newborn (PPHN), aligning with the current standard of care at 20 ppm.
The technology offers several advantages over cylinder-based systems: unlimited on-demand NO generation, minimal NO₂ byproduct production, effective filtration through Smart Filters, and seamless integration with ventilator circuits. Each disposable Smart Filter provides 12 hours of uninterrupted therapy regardless of ventilator demands.
This agreement strategically positions Beyond Air to accelerate market penetration. By eliminating procurement barriers through Premier's pre-negotiated pricing and terms, the sales process is streamlined for hospitals considering conversion from legacy NO delivery systems. The agreement effectively creates a direct commercial pathway to Premier's extensive hospital network, potentially accelerating adoption of the LungFit PH platform in clinical settings where nitric oxide therapy is required.
GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, has been awarded a national group purchasing agreement for therapeutic gases with Premier, Inc. Effective July 15th, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the LungFit PH system and disposable NO2 Smart Filters.
“We are proud to have been awarded this agreement with Premier, expanding access to our LungFit PH system across their extensive network of U.S. hospitals and healthcare providers. The agreement helps streamline the sales process for the Premier hospital network as they contemplate converting their NO supply to the LungFit PH system,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. “Our innovative cylinder-free NO delivery system represents a transformative advancement compared to the legacy cylinder-based NO systems.”
The LungFit PH platform uses patented Ionizer™ technology to generate unlimited, on-demand nitric oxide from ambient air, which is then able to be delivered directly to a ventilator circuit, regardless of dose or flow. Using only the power equivalent to a 60-watt lightbulb, the system ionizes nitrogen and oxygen molecules to form nitric oxide, while producing only minimal levels of nitrogen dioxide (NO2) as a byproduct. A built-in Smart Filter then effectively removes NO₂ from the internal circuit, ensuring safe delivery to the patient
For the treatment of PPHN, the novel LungFit PH system is designed to deliver NO doses consistent with the current standard of care for delivery of 20 ppm NO, with a range of 0.5 ppm – 80 ppm (low concentration NO), for ventilated patients. Each Smart Filter provides 12 hours of therapy regardless of ventilator demands and can be replaced in seconds for uninterrupted treatment.
Premier is a leading technology-driven healthcare improvement company, providing solutions to two-thirds of all healthcare providers in the U.S. Playing a critical role in the rapidly evolving healthcare industry, Premier unites providers, suppliers, payers and policymakers to make healthcare better with national scale, smarter with actionable intelligence and faster with novel technologies. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.
This Premier contract was negotiated with the support of Beyond Air strategic partner, HealthCare Links, a corporate account consulting group specializing in national GPO access and alignment.
About LungFit *
Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits.
LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.
*Beyond Air's LungFit PH is approved for commercial use in the United States, European Union, Australia, Thailand, Saudi Arabia, Taiwan and New Zealand. Beyond Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.
About Beyond Air®, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACTS:
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
What is the new agreement between Beyond Air (XAIR) and Premier Inc?
How does Beyond Air's LungFit PH system work?
What are the advantages of Beyond Air's LungFit PH system over traditional methods?
How long do the Smart Filters last in Beyond Air's LungFit PH system?
What is the dosage range of Beyond Air's LungFit PH system?
